GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Remedent Inc (OTCPK:REMI) » Definitions » COGS-to-Revenue

Remedent (Remedent) COGS-to-Revenue : 0.38 (As of Dec. 2020)


View and export this data going back to 2000. Start your Free Trial

What is Remedent COGS-to-Revenue?

Remedent's Cost of Goods Sold for the three months ended in Dec. 2020 was $0.13 Mil. Its Revenue for the three months ended in Dec. 2020 was $0.34 Mil.

Remedent's COGS to Revenue for the three months ended in Dec. 2020 was 0.38.

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin. Remedent's Gross Margin % for the three months ended in Dec. 2020 was 62.02%.

Remedent COGS-to-Revenue Historical Data

The historical data trend for Remedent's COGS-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Remedent COGS-to-Revenue Chart

Remedent Annual Data
Trend Mar11 Mar12 Mar13 Mar14 Mar15 Mar16 Mar17 Mar18 Mar19 Mar20
COGS-to-Revenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.29 0.50 0.34 0.30 0.30

Remedent Quarterly Data
Mar16 Jun16 Sep16 Dec16 Mar17 Jun17 Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20
COGS-to-Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.36 0.33 0.30 0.35 0.38

Remedent COGS-to-Revenue Calculation

Remedent's COGS to Revenue for the fiscal year that ended in Mar. 2020 is calculated as

COGS to Revenue=Cost of Goods Sold / Revenue
=0.322 / 1.064
=0.30

Remedent's COGS to Revenue for the quarter that ended in Dec. 2020 is calculated as

COGS to Revenue=Cost of Goods Sold / Revenue
=0.128 / 0.337
=0.38

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Remedent  (OTCPK:REMI) COGS-to-Revenue Explanation

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin.

Remedent's Gross Margin % for the three months ended in Dec. 2020 is calculated as:

Gross Margin %=1 - COGS to Revenue
=1 - Cost of Goods Sold / Revenue
=1 - 0.128 / 0.337
=62.02 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

A company that has a moat can usually maintain or even expand their Gross Margin. A company can increase its Gross Margin in two ways. It can increase the prices of the goods it sells and keeps its Cost of Goods Sold unchanged. Or it can keep the sales price unchanged and squeeze its suppliers to reduce the Cost of Goods Sold. Warren Buffett believes businesses with the power to raise prices have moats.

Remedent COGS-to-Revenue Related Terms

Thank you for viewing the detailed overview of Remedent's COGS-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

Remedent (Remedent) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Remedent Inc (OTCPK:REMI) » Definitions » COGS-to-Revenue
Comparable Companies
SECI RSCF OZSC ASNB WHSI VLRXQ NURO ECIA POAI ELGX BDX ISRG XPAR:EL BAX OCSE:COLO B TSE:7741 XSWX:ALC TSE:4543 XPAR:DIM RMD
Traded in Other Exchanges
N/A
Address
Zuiderlaan 1-3, Box 8, Ghent, BEL, 9000
Website
https://www.remedent.com
Remedent Inc is a manufacturer of cosmetic dentistry products in Europe. The company is engaged in the research, development, and manufacturing of oral care and cosmetic dentistry products. It designs, develops, manufactures, and distributes cosmetic dentistry products, including a full line of professional dental products that are distributed in Europe, Asia, the Middle East, and the United States. The product line of the company includes SmileWise, the SmileMe mirror, and the Condor intra-oral 3D scanner.
Executives
Stuart Steinberg 10 percent owner 85 BELLEVUE AVENUE, RYE NY 10580
Marxe Austin W & Greenhouse David M 10 percent owner C/O SPECIAL SITUATIONS FUNDS, 527 MADISON AVENUE, SUITE 2600, NEW YORK NY 10022
Gruber & Mcbaine Capital Management Llc 10 percent owner 234 VAN NESS, STE 5, SAN FRANCISCO CA 94133
Stephen Farley Ross director, officer: CFO; Secretary XAVIER DE COCKLAAN 42 DEURLE C9 9831
Fred Kolsteeg director XAVIER DE COCKLAAN 42 DEURLE C9 9831
Acker Philippe Van director C/O REMEDENT, INC. XAVIER DE COCKLAAN 42 9831 DEURLE C9 9831
Robin List other: Former Officer and Director XAVIER DE COCKLAAN 42 DEURLE C9 9831
Roger Leddington officer: Sr VP & Head of US Marketing C/O REMEDENT, INC. XAVIER DE COCKLAAN 42 DEURLE C9 9831
Guy Devreese director, officer: Chairman of the Board XAVIER DE COCKLAAN 42 DEURLE C9 9831
Judd Darrin Hoffman officer: VP Worldwide Sales/Operations 702A JUANITA AVENUE REDONDO BEACH CA 90277
Nv Lausha 10 percent owner C/O REMEDENT, INC. XAVIER DE COCKLAAN 42 9831 DEURLE C9 9831

Remedent (Remedent) Headlines

From GuruFocus

Making Money from Smiles

By Frank Lind Frank Lind • 05-26-2011